UB Paderborn / Katalog / Suche / in CDI

Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

European urology open science (Online), 2020-07, Vol.19, p.e1389-e1390

2020

Link zum Volltext

Verfügbarkeit prüfen

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment

European urology open science (Online), 2020-07, Vol.19, p.e865-e866

2020

Link zum Volltext

Verfügbarkeit prüfen

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

European journal of cancer (1990), 2014-11, Vol.50, p.8-8

2014

Link zum Volltext

Verfügbarkeit prüfen

P312 - Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guérin (BCG)– unresponsive High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC)

European urology, 2024-03, Vol.85, p.S433-S433

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guérin (BCG)– unresponsive High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC)

European urology, 2024-03, Vol.85, p.S433

2024

Link zum Volltext

Verfügbarkeit prüfen

A0522 - Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C

European urology, 2023-02, Vol.83, p.S748-S748

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

European urology, 2023-02, Vol.83, p.S1725-S1726

2023

Link zum Volltext

Verfügbarkeit prüfen

A1193 - Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

European urology, 2023-02, Vol.83, p.S1725-S1726

2023

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C

European urology, 2023-02, Vol.83, p.S748

2023

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?

Prostate cancer and prostatic diseases, 2013-03, Vol.16 (1), p.1

Shore, N.D

2013

Link zum Volltext

Verfügbarkeit prüfen

1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study

Annals of oncology, 2023-10, Vol.34, p.S984-S984

2023

Link zum Volltext

Verfügbarkeit prüfen

Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303

European urology, 2023-02, Vol.83, p.S751

2023

Link zum Volltext

Verfügbarkeit prüfen

A0525 - Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303

European urology, 2023-02, Vol.83, p.S751-S751

2023

Link zum Volltext

Verfügbarkeit prüfen

1386P 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)

Annals of oncology, 2022-09, Vol.33, p.S1177

2022

Link zum Volltext

Verfügbarkeit prüfen

1385P Transcriptome-based prognostic and predictive biomarker analysis of ENACT: A randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)

Annals of oncology, 2022-09, Vol.33, p.S1176

2022

Link zum Volltext

Verfügbarkeit prüfen

Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

European urology, 2024-03, Vol.85, p.S213-S214

2024

Link zum Volltext

Verfügbarkeit prüfen

P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

European urology, 2024-03, Vol.85, p.S213-S214

2024

Link zum Volltext

Verfügbarkeit prüfen

233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study

Annals of oncology, 2020-11, Vol.31, p.S1332-S1333

2020

Link zum Volltext

Verfügbarkeit prüfen

1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)

Annals of oncology, 2023-10, Vol.34, p.S997-S998

2023

Link zum Volltext

Verfügbarkeit prüfen

639TiP KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE)

Annals of oncology, 2021-09, Vol.32, p.S669-S669

2021

Link zum Volltext

Verfügbarkeit prüfen

645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

Annals of oncology, 2021-09, Vol.32, p.S672-S673

2021

Link zum Volltext

Verfügbarkeit prüfen

640TiP Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F

Annals of oncology, 2021-09, Vol.32, p.S669-S670

2021

Link zum Volltext

Verfügbarkeit prüfen

648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC

Annals of oncology, 2021-09, Vol.32, p.S675-S676

2021

Link zum Volltext

Verfügbarkeit prüfen

641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H

Annals of oncology, 2021-09, Vol.32, p.S670-S671

2021

Link zum Volltext

Verfügbarkeit prüfen

718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

Annals of oncology, 2021-09, Vol.32, p.S723-S723

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

P312 - Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guérin (BCG)– unresponsive High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guérin (BCG)– unresponsive High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC)

A0522 - Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C

Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

A1193 - Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C

Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?

1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study

Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303

A0525 - Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303

1386P 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)

1385P Transcriptome-based prognostic and predictive biomarker analysis of ENACT: A randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)

Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study

1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)

639TiP KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE)

645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

640TiP Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F

648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC

641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H

718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

Suchergebnisse filtern